A Risk Matrix Approach to Validation/Verification of Antibodies for IHC

The session will start with an introduction to main concepts such as; the difference between antibody validation vs. verification, explaining the clinical risk to patients, the usefulness of a risk matrix covering the use of antibodies from low risk to high risk, and how this is decided. It will highlight the risk matrix we use in my lab in Melbourne, Australia, and offer it up for discussion with the audience. I hope to cover the similarities and differences (if any) between the Australian and American lab accreditation systems on the subject of antibody validation, especially with IVD, RUO, and ASR antibody classifications.

CEUs: This histology course is worth 1 continuing education credit. Course is available for 365 days from date of registration.